Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A333 alone or with Tislelizumab in Advanced Solid Tumors
NCT03379259Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Nov 2017
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of garivulimab in solid tumor (advanced stage), sponsored by BeiGene. Started Nov 2017; status: terminated.
02
Drugs
garivulimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03379259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379259.